RLMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RLMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Relmada Therapeutics's share price is $0.4175. Relmada Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $1.58. Hence, Relmada Therapeutics's PB Ratio of today is 0.26.
Good Sign:
Relmada Therapeutics Inc stock PB Ratio (=0.3) is close to 10-year low of 0.27
The historical rank and industry rank for Relmada Therapeutics's PB Ratio or its related term are showing as below:
During the past 11 years, Relmada Therapeutics's highest PB Ratio was 41.50. The lowest was 0.26. And the median was 3.97.
During the past 12 months, Relmada Therapeutics's average Book Value Per Share Growth Rate was -52.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -24.00% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Relmada Therapeutics was 563.80% per year. The lowest was -30.60% per year. And the median was 81.50% per year.
The historical data trend for Relmada Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relmada Therapeutics Annual Data | |||||||||||||||||||||
Trend | Aug13 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 9.50 | 4.96 | 3.00 | 0.75 | 1.46 |
Relmada Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | 0.90 | 1.46 | 1.95 | 1.47 | 2.05 |
For the Biotechnology subindustry, Relmada Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Relmada Therapeutics's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.4175 | / | 1.578 | |
= | 0.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Relmada Therapeutics (NAS:RLMD) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Relmada Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Sergio Traversa | director, officer: Chief Executive Officer | 138 CANTERBURY LN, BLUE BELL PA 19422 |
Maged Shenouda | director | 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011 |
Paul Edward Kelly | director | 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Chuck Ence | officer: Chief Financial Officer | 3000 S. UNIVERSITY BLVD., DENVER CO 80210 |
Cedric O'gorman | officer: Chief Medical Officer | C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134 |
Fabiana Fedeli | director | C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134 |
Thomas Wessel | officer: EVP, Head of R&D | 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
Eric Thomas Schmidt | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
John Glasspool | director | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Ottavio V. Vitolo | officer: Chief Medical Officer | 71 WESTLAND AVENUE, NEWTON MA 02465 |
Shreeram Agharkar | director | P.O BOX 2042, PRINCETON NJ 08543 |
Sandesh Seth | director | 300 E 93RD STREET, #20-B, NEW YORK NY 10128 |
Lisa Nolan | officer: Chief Business Officer | 36 ROCKLAND MILLS, ROCKLAND DE 19732 |
Eliseo Oreste Salinas | officer: President and CSO | 7707 GATEWAY BLVD, NEWARK CA 94560 |
From GuruFocus
By GuruFocus Research • 03-19-2024
By GuruFocus Research • 05-09-2024
By Marketwired • 11-19-2024
By PRNewswire • 09-17-2024
By Marketwired • 11-14-2024
By PRNewswire • 06-03-2024
By GuruFocus News • 11-14-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 08-07-2024
By Marketwired • 09-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.